Analyst Price Target is $7.00
▲ +141.38% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Anebulo Pharmaceuticals in the last 3 months. The average price target is $7.00, with a high forecast of $8.00 and a low forecast of $6.00. The average price target represents a 141.38% upside from the last price of $2.90.
Current Consensus is
The current consensus among 2 investment analysts is to buy stock in Anebulo Pharmaceuticals.
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. The company was incorporated in 2020 and is based in Lakeway, Texas.